QTTB
Q32 Bio Inc.
Research: Finviz ↗·Perplexity ↗
No convergence signal this quarter — shown because tracked funds have filed 13D/G on this stock.
News Summary
PositiveQ32 Bio reported positive Phase 2a data for bempikibart in alopecia areata (35.3% mean SALT score improvement, 40% SALT-20 response rate), triggering a dramatic stock rally from low $12s to high teens and enabling a $200 million capital raise to fund continued development. Despite the clinical success and analyst upgrade to $36 PT, the company remains unprofitable ($8.9M net loss in Q2 2026, ($0.44) EPS) with execution risk on Phase 2b advancement and commercialization.
Fund 13D/13G Filings (3)
Tracked funds' beneficial-ownership filings on this stock — disclosed within days of a position change, fresher than the quarterly 13F. Since Filing compares the stock to SPY from the filing date (shown for filings within the last 90 days).
Tracked Funds Holding (1)
| Fund | Manager | Shares Held | Position Value |
|---|---|---|---|
| Point72 | Steve Cohen | 1.2M | $15M |
Quarter-end 13F positions for the tracked funds holding this stock.